Advanced search
Publication Cover
Therapeutic Delivery Volume 1, 2010 - Issue 3
Submit an article Journal homepage
113
Views
0
CrossRef citations to date
0
Altmetric
Review

Advances in Effective Vaccine Development Against Hepatitis B: Focus on Mucosal Vaccine Delivery Strategies

Rishi Paliwal1 Drug Delivery Research Laboratory Department of Pharmaceutical Sciences Dr. H. S. Gour [email protected]
,
Shivani R Paliwal1 Drug Delivery Research Laboratory Department of Pharmaceutical Sciences Dr. H. S. Gour [email protected]
&
Suresh P Vyas1 Drug Delivery Research Laboratory Department of Pharmaceutical Sciences Dr. H. S. Gour [email protected]
Pages 397-410 | Published online: 15 Sep 2010

Bibliography

  • Hilleman MR . Critical overview and outlook: pathogenesis, prevention and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus. Vaccine21, 4626–4649 (2003).
  • Chisari FV , FerrariC. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol.13, 29–60 (1995).
  • Jaganathan KS , VyasSP. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. Vaccine24, 4201–4211 (2006).
  • Kane M . Reduced doses of hepatitis B vaccines: is it a good idea? Bull. WHO73, 529–530 (1995).
  • Feng L , ZhouXJ, QiXR. Preparation, release and immunogenicity evaluation of HBsAg-PLGA microspheres. Beijing Da Xue Xue Bao.37, 527–531 (2005).
  • Feng L , ZhouXJ, WangSC, JiangY, QiXR. Immunogenicity of single-dose HBsAg-PLGA controlled release microspheres in mice. Yao Xue Xue Bao.41, 132–137 (2006).
  • Feng L , QiXR, ZhouXJet al. Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres. J. Control. Release 112, 35–42 (2006).
  • Jaganathan KS , SinghP, PrabakaranD, MishraV, VyasSP. Development of a single-dose stabilized poly(D,L-lactic-co-glycolic acid) microspheres-based vaccine against hepatitis B. J. Pharm. Pharmacol.56, 1243–1250 (2004).
  • Aguado MT . Future approaches to vaccine development: single-dose vaccines using controlled release delivery systems. Vaccine11, 596–597 (1993).
  • Goyal AK , RawatA, MahorS, GuptaPN, KhatriK, VyasSP. Nanodecoy system: a novel approach to design hepatitis B vaccine for immunopotentiation. Int. J. Pharm.309, 227–233 (2006).
  • Bharali DJ , MousaSA, ThanavalaY. Micro- and nanoparticle-based vaccines for hepatitis B. Adv. Exp. Med. Biol.601, 415–421 (2007).
  • Bharali DJ , PradhanV, ElkinGet al. Novel nanoparticles for the delivery of recombinant hepatitis B vaccine. Nanomedicine 4, 311–317 (2008).
  • Nossal JV . The global alliance for vaccines and immunization – a millennial challenge. Nat. Immunol.1, 5–8 (2000).
  • Sanyal G , ShiL. A review of multiple approaches towards an improved hepatitis B vaccine. Expert Opin. Ther. Pat.19, 59–72 (2009).
  • Davis SS . Nasal vaccines. Adv. Drug Deliv. Rev.51, 21–42 (2001).
  • Gramzinski RA , MillanCL, ObaldiaN, HoffmanSL, DavisHL. Immune response to a hepatitis B DNA vaccine in Aotus monkeys: a comparison of vaccine formulation, route, and method of administration. Mol. Med.4, 109–118 (1998).
  • Vyas SP , SinghRP, JainSet al. Non-ionic surfactant based vesicles (niosomes) for noninvasive topical genetic immunization against hepatitis B. Int. J. Pharm. 296, 80–86 (2005).
  • Tiollais P , PourcelC, DejeanA. The hepatitis B virus. Nature317, 489–495 (1985).
  • Fattovich G . Natural history of hepatitis B. J. Hepatol.39, S50–58 (2003).
  • Khatri K , RawatA, MahorS, GuptaPN, VyasSP. Hepatitis B surface protein docked vesicular carrier for site specific delivery to liver. J. Drug Target.13, 359–366 (2005).
  • Chisari FV , FerrariC. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol.13, 29–60 (1995).
  • McAuliffe VJ , PurcellRH, GerinJL. Type B hepatitis: a review of current prospects for a safe and effective vaccine. Rev. Infect. Dis.2, 470–492 (1980).
  • McAleer WJ , BuynakEB, MaigetterRZ, WamplerDE, MillerWJ, HillemanMR. Human hepatitis B vaccine from recombinant yeast. Nature307, 178–180 (1984).
  • Hauser P , VoetP, SimoenEet al. Immunological properties of recombinant HBsAg produced in yeast. Postgrad. Med. J. 63, 83–91 (1987).
  • Thoelen S , De Clercq N, Tornieporth N. A prophylactic hepatitis B vaccine with a novel adjuvant system. Vaccine19, 2400–2403 (2001).
  • Moynihan JS , HowardCR. Recent advances in the development of peptide vaccines for hepatitis B. Intervirology44, 65–77 (2001).
  • McCluskie MJ , DavisHL. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J. Immunol.161, 4463–4466 (1998).
  • McCluskie MJ , WeeratnaRD, PayettePJ, DavisHL. Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA. FEMS Immunol. Med. Microbiol.32, 179–185 (2002).
  • Jain V , SahuR, Misra-BhattacharyaS, VyasSP, KohliD. Enhancement of T-helper type I immune responses against hepatitis B surface antigen by LPS derivatives adjuvanted liposomes delivery system. J. Drug Target.6, 706–715 (2008).
  • Jain V , VyasSP, KohliDV. Well-defined and potent liposomal hepatitis B vaccines adjuvanted with lipophilic MDP derivatives. Nanomedicine5, 334–344 (2009).
  • Pandey RS , DixitVK. Evaluation of ISCOMs for immunization against hepatitis B. Curr. Pharm. Biotechnol.10, 709–716 (2009).
  • Pandey RS , DixitVK. Evaluation of ISCOM vaccines for mucosal immunization against hepatitis B. J. Drug Target. (2009) (In Press).
  • Guan XJ , GuanXJ, WuYZ, JiaZC, ShiTD, TangY. Construction and characterization of an experimental ISCOMS-based hepatitis B polypeptide vaccine. World. J. Gastroenterol.8, 294–297 (2002).
  • Lutsiak CM , SosnowskiDL, WishartDS, KwonGS, SamuelJ. Use of a liposome antigen delivery system to alter immune responses in vivo. J. Pharm. Sci.87, 1428–1432 (1998).
  • Shi L , CaulfieldMJ, ChernRT, WilsonRA, SanyalG, VolkinDB. Pharmaceutical and immunological evaluation of a single-shot hepatitis B vaccine formulated with PLGA microspheres. J. Pharm. Sci.91, 1019–1035 (2002).
  • Shukla A , KhatriK, GuptaPN, GoyalAK, MehtaA, VyasSP. Oral immunization against hepatitis B using bile salt stabilized vesicles (bilosomes). J. Pharm. Sci.11, 59–66 (2008).
  • Perrie Y , FrederikPM, GregoriadisG. Liposome-mediated DNA vaccination: the effect of vesicle composition. Vaccine19, 3301–3310 (2001).
  • Saini V , SahooMK, MurthyPK, KohliD. Polymeric lamellar substrate particles as carrier adjuvant for recombinant hepatitis B surface antigen vaccine. Vaccine27, 2372–2378 (2009).
  • Papaevangelou G . Current combined vaccines with hepatitis B. Vaccine.16 (Suppl.), S69–S72 (1998).
  • Mutwiri G , BenjaminP, SoitaH, BabiukLA. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen. Vaccine26, 2680–2688 (2008).
  • Xie Y , SunHX, LiD. Platycodin D is a potent adjuvant of specific cellular and humoral immune responses against recombinant hepatitis B antigen. Vaccine27, 757–764 (2009).
  • Xie Y , HeSW, SunHX, LiD. Platycodin D2 improves specific cellular and humoral responses to hepatitis B surface antigen in mice. Chem. Biodivers.7, 178–185 (2010).
  • Chong CS , CaoM, WongWWet al. Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery. J. Control. Release. 102, 85–99 (2005).
  • Jain S , SinghP, MishraV, VyasSP. Mannosylated niosomes as adjuvant-carrier system for oral genetic immunization against hepatitis B. Immunol. Lett.101, 41–49 (2005).
  • Gupta PN , MahorS, RawatA, KhatriK, GoyalA, VyasSP. Lectin anchored stabilized biodegradable nanoparticles for oral immunization 1. Development and in vitro evaluation. Int. J. Pharm.318, 163–173 (2006).
  • Gupta PN , KhatriK, GoyalAK, MishraN, VyasSP. M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B. J. Drug Target.15, 701–713 (2007).
  • Khatri K , GoyalAK, GuptaPN, MishraN, VyasSP. Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B. Int. J. Pharm.354, 235–241 (2008).
  • Khatri K , GoyalAK, GuptaPN, MishraN, MehtaA, VyasSP. Surface modified liposomes for nasal delivery of DNA vaccine. Vaccine26, 2225–2233 (2008).
  • Vyas SP , GuptaPN. Implication of nanoparticles/microparticles in mucosal vaccine delivery. Expert. Rev. Vaccines6, 401–418 (2007).
  • Malik B , GoyalAK, MangalS, ZakirF, VyasSP. Implication of gut immunology in the design of oral vaccines. Curr. Mol. Med. (2009) (In Press).
  • Chadwick S , KriegelC, AmijiM. Nanotechnology solutions for mucosal immunization. Adv. Drug Deliv. Rev. (2009) (In Press).
  • Simerska P , MoylePM, OliveC, TothI. Oral vaccine delivery – new strategies and technologies. Curr. Drug Deliv.6, 347–358 (2009).
  • Shukla A , KatareOP, SinghB, VyasSP. M-cell targeted delivery of recombinant hepatitis B surface antigen using cholera toxin B subunit conjugated bilosomes. Int. J. Pharm.385, 47–52 (2010).
  • Jain AK , GoyalAK, MishraN, VaidyaB, MangalS, VyasSP. PEG-PLA-PEG block copolymeric nanoparticles for oral immunization against hepatitis B. Int. J. Pharm. (2009) (In Press).
  • Partidos CD . Intranasal vaccines: forthcoming challenges. Pharm. Sci. Technol. Today3, 273–280 (2000).
  • Borges O , Cordeiro-da-SilvaA, TavaresJ, SantarémN, de Sousa A, Borchard G, Junginger HE. Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles. Eur. J. Pharm. Biopharm.69, 405–416 (2008).
  • Jain AK , GoyalAK, GuptaPNet al. Synthesis, characterization and evaluation of novel triblock copolymer based nanoparticles for vaccine delivery against hepatitis B. J. Control. Release 136, 161–169 (2009).
  • Pawar D , GoyalAK, MangalSet al. Evaluation of mucoadhesive PLGA microparticles for nasal immunization. AAPS J. (2010) (In Press).
  • Kim TW , ChungH, KwonICet al. Induction of immunity against hepatitis B virus surface antigen by intranasal DNA vaccination using a cationic emulsion as a mucosal gene carrier. Mol. Cells 22, 175–181 (2006).
  • Mahor S , GuptaPN, RawatA, VyasSP. A needle-free approach for topical immunization: antigen delivery via vesicular carrier system(s). Curr. Med. Chem.14, 2898–2910 (2007).
  • Paul A , CevcG, BachhawatBK. Transdermal immunisation with an integral membrane component, gap junction protein, by means of ultradeformable drug carriers, transfersomes. Vaccine16, 188–195 (1998).
  • Mahor S , RawatA, DubeyPKet al. Cationic transfersomes based topical genetic vaccine against hepatitis B. Int. J. Pharm. 340, 13–19 (2007).
  • Mishra D , DubeyV, AsthanaA, SarafDK, JainNK. Elastic liposomes mediated transcutaneous immunization against Hepatitis B. Vaccine24, 4847–4855 (2006).
  • Mishra D , MishraPK, DubeyV, DabadghaoS, JainNK. Evaluation of uptake and generation of immune response by murine dendritic cells pulsed with hepatitis B surface antigen-loaded elastic liposomes. Vaccine25, 6939–6944 (2007).
  • Mishra D , MishraPK, DubeyV, NaharM, DabadghaoS, JainNK. Systemic and mucosal immune response induced by transcutaneous immunization using Hepatitis B surface antigen-loaded modified liposomes. Eur. J. Pharm. Sci.33, 424–433 (2008).
  • Hilleman MR . Plasma-derived hepatitis B vaccine – a breakthrough in preventive medicine. In: Hepatitis B Vaccines in Clinical Practice. Ellis RW (Ed.). Dekker, NY, USA, 17–39 (1992).
  • Gretty RJ . Recombinant hepatitis B vaccines. In: Viral Hepatitis and Liver Disease. Zuckerman AJ, Alan R (Eds). NY, USA, 1017–1024 (1988).
  • Stephenne J . Development and production aspects of a recombinant yeast derived hepatitis vaccine. Vaccine8, S69–S73 (1990).
  • Tacket CO , RoyMJ, WideraG, SwainWF, BroomeS, EdelmanR. Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine17, 2826–2829 (1999).
  • Rottinghaus ST , PolandGA, JacobsonRM, BarrLJ, RoyMJ. Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination. . Vaccine21, 4604–4608 (2003).
  • He XW , WangF, JiangLet al. Induction of mucosal and systemic immune response by single-dose oral immunization with biodegradable microparticles containing DNA encoding HBs. Ag. J. Gen. Virol. 86, 601–610 (2005).
  • Debin A , KravtzoffR, SantiagoJVet al. Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses. Vaccine 20, 2752–2763 (2002).
  • Wang J , HuJH, LiFQet al. Strong cellular and humoral immune responses induced by transcutaneous immunization with HBsAg DNA-cationic deformable liposome complex. Exp. Dermatol. 16, 724–729 (2007).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.